Research Article
Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
Table 2
Comparisons before and after intervention with anti-TNF treatment (results presented as mean ± SD).
| | Baseline () | 6 months after anti-TNF () | value |
| | Age (years) | 43.1 ± 10.8 | | Gender | 7 M/5 F | | BMI (kg/m2) | 23.8 ± 1.4 | 24.1 ± 1.5 | ns | | Fasting glucose (mg/dl) | 103 ± 5.9 | 96.5 ± 10.2 | ns | | Insulin (μIU/ml) | 15.5 ± 5.9 | 9.9 ± 2.9 | 0.042 | | C-peptide (ng/ml) | 2.4 ± 1 | 1.3 ± 0.4 | 0.030 | | HbA1c (%) | 5.4 ± 0.3 | 5.2 ± 0.3 | ns | | Cholesterol (mg/dl) | 176.8 ± 35.2 | 167.6 ± 36.8 | ns | | HDL (mg/dl) | 49.6 ± 18.6 | 51.4 ± 11.9 | ns | | LDL (mg/dl) | 98.5 ± 26.7 | 94.7 ± 36.2 | ns | | Triglycerides (mg/dl) | 138.9 ± 62.5 | 114.2 ± 57.5 | ns | | CRP (mg/l) | 6.1 ± 8 | 5.2 ± 8.1 | ns | | HOMA-IR | 4.2 ± 1.9 | 2.2 ± 0.9 | 0.045 |
|
|
AMSs: aminosalicylates; BMI: body mass index; CRP: C-reactive protein; HDL: high-density lipoprotein; HOMA-IR: homeostatic model assessment insulin resistance; LDL: low-density lipoprotein; TNFα: tumor necrosis factor alpha.
|
